UNITED THERAPEUTICS Corp
UTHR evidence brief
What we can confirm
- BioSniper Score:
- 7.5 / 10
- Market Cap:
- $21.36B
- Lead Asset:
- Adcirca (Approved)
What it means
What to watch
Prepared research question
What matters most for UTHR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UTHR
United Therapeutics Corp (UTHR) is a publicly traded biotechnology company focused on developing therapies for cardiopulmonary diseases and advancing xenotransplantation, with a marketed inhaled prostacyclin franchise (Tyvaso) and a pipeline including ralinepag and gene-edited organ transplants.
Key risk: Competitive pressure in prostacyclin market
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 264 clinical trials · 6 catalysts for UNITED THERAPEUTICS Corp.
United Therapeutics Corp (UTHR) is a publicly traded biotechnology company focused on developing therapies for cardiopulmonary diseases and advancing xenotransplantation, with a marketed inhaled prostacyclin franchise (Tyvaso) and a pipeline including ralinepag and gene-edited organ transplants.
- Cash & equivalents of $1,803.2M as of 2026-06-30 [sec].
- Total revenue of $783.3M and net income of $333.0M as of 2026-06-30 [sec].
- Phase 3 TETON-1 trial of nebulized Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint with improved lung function and reduced risk of clinical worsening [news · 2026-04-01].
- FDA clearance received for a first-of-its-kind clinical study to transplant gene-edited pig hearts (UHeart) into humans with end-stage heart failure [news · 2026-05-22].
- Goldman Sachs initiated coverage with a Sell rating, even as the company pursues 14 potential launches and a $2.00 billion share repurchase authorization [news · 2026-09-27].
What works
- Strong cash position of $1,803.2M as of 2026-06-30 provides financial flexibility for pipeline investment and share repurchases [sec].
- Positive Phase 3 TETON-1 data for Tyvaso in IPF supports a planned supplemental FDA filing, potentially expanding the Tyvaso franchise [news · 2026-04-01].
- FDA clearance for a xenotransplantation trial (UHeart) positions the company at the forefront of a novel therapeutic area [news · 2026-05-22].
- Ambitious pipeline of 14 potential launches, including ralinepag and nebulized Tyvaso for IPF, indicates multiple growth catalysts [news · 2026-09-27].
What to weigh
- Goldman Sachs initiated coverage with a Sell rating, citing competitive dynamics in the inhaled prostacyclin market [news · 2026-09-27].
- Revenue was flat sequentially in Q2 2026, with management highlighting competitive pressures [news · 2026-08-14].
- Xenotransplantation efforts (e.g., xenokidney, UHeart) are long-horizon projects with uncertain timelines and regulatory hurdles [news · 2026-09-27].
- Patent expiries for key products (FERRIC CARBOXYMALTOSE in 2028, TREPROSTINIL in 2029 and 2042) could eventually expose revenue to generic competition [catalyst].
From the filings
Quoted directly from source documents.
Phase 3 TETON-1 trial met primary endpoint
“Phase 3 TETON-1 trial of nebulized Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint, showing a statistically significant improvement in lung function and reduced risk of clinical worsening over 52 weeks with no new safety signals”
News · April 1, 2026
FDA clearance for UHeart xenotransplantation study
“United Therapeutics (NasdaqGS:UTHR) received FDA clearance for a first-of-its-kind clinical study to transplant gene-edited pig hearts, known as UHeart, into human patients with end-stage heart failure”
News · May 22, 2026
Goldman Sachs Sell rating and $2B buyback authorization
“Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization”
News · September 27, 2026
Catalyst timeline
- 2026-11-01 · Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD) — Initiation of a Phase 2 xenotransplantation trial for kidney disease, a novel and high-risk program.
- 2026-11-01 · Phase2_Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis — Start of a Phase 2 combination study for myelofibrosis, expanding the pipeline beyond cardiopulmonary.
- 2028-02-15 · Patent_Expiry · FERRIC CARBOXYMALTOSE — Patent_Expiry: NDA203565 — Patent expiry for FERRIC CARBOXYMALTOSE could open the door to generic competition.
- 2029-03-29 · Patent_Expiry · TREPROSTINIL — Patent_Expiry: NDA021272 — Patent expiry for TREPROSTINIL, a key product, may affect revenue.
- 2031-08-11 · Patent_Expiry · TREPROSTINIL DIOLAMINE — Patent_Expiry: NDA203496 — Patent expiry for TREPROSTINIL DIOLAMINE, another formulation of the prostacyclin analogue.
- 2042-02-03 · Patent_Expiry · TREPROSTINIL — Patent_Expiry: NDA214324 — Later patent expiry for TREPROSTINIL, providing extended exclusivity for certain formulations.
Risks & what to watch (4)›
Key risks
- Competitive pressure in prostacyclin market — Q2 2026 revenue flat sequentially; management highlighted competitive dynamics in inhaled prostacyclin market [news · 2026-08-14].
- Patent expiries for key products — FERRIC CARBOXYMALTOSE patent expires 2028-02-15; TREPROSTINIL patents expire 2029 and 2042 [catalyst].
- Long-horizon xenotransplantation uncertainty — Xenokidney and UHeart trials are early-stage with no near-term revenue; regulatory and clinical risks high [news · 2026-09-27].
- Sell rating from Goldman Sachs — Goldman Sachs initiated coverage with a Sell rating, potentially affecting investor sentiment [news · 2026-09-27].
What to watch
- Top-line results from Phase 3 Tyvaso study for PPF expected in second half of 2027 [news · 2026-08-18].
- Regulatory filings for Tyvaso IPF and ralinepag; PDUFA dates could drive near-term growth [news · 2026-09-23].
- Progress of xenotransplantation trials (xenokidney Phase 2 start 2026-11-01; UHeart) [catalyst].
- Share repurchase execution under the $2.00B authorization and its impact on stock price [news · 2026-09-27].
Sources: Catalysts · News · Generated October 4, 2026 · How we verify sources →
Run UNITED THERAPEUTICS Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available UNITED THERAPEUTICS Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.13 · 8% dilution
Lead: Approved
5 candidates
6 upcoming, next in ~18d
1 buy · 1249 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 8.2%
- Days to cover
- 4.2
- Shares short
- 2,703,199
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UTHR short interestGovernance
Frequently asked questions
What is the AI investment thesis for UNITED THERAPEUTICS Corp?
United Therapeutics Corp (UTHR) is a publicly traded biotechnology company focused on developing therapies for cardiopulmonary diseases and advancing xenotransplantation, with a marketed inhaled prostacyclin franchise (Tyvaso) and a pipeline including ralinepag and gene-edited organ transplants.
What is UNITED THERAPEUTICS Corp's lead drug candidate?
UNITED THERAPEUTICS Corp's most advanced tracked candidate is Adcirca (Approved) for Pulmonary arterial hypertension (PAH).
What is UNITED THERAPEUTICS Corp's next catalyst?
UNITED THERAPEUTICS Corp's next tracked catalyst is a Phase2_Start event — "Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)" — expected November 1, 2026.
Who is the CEO of UNITED THERAPEUTICS Corp?
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. is the chief executive officer of UNITED THERAPEUTICS Corp (UTHR).
Where is UNITED THERAPEUTICS Corp headquartered?
UNITED THERAPEUTICS Corp (UTHR) is headquartered in Silver Spring, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.